A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →. With Ono Pharmaceutical Co., Ltd..
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
545actual
Sites
184
Countries
Argentina, Australia, Austria +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-04-18 | actual | When the study began enrolling |
| Primary completion | 2026-05-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-05-27 | estimated | The whole study's end, after follow-up |
| First posted | 2017-12-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hepatocellular Carcinoma
- Liver Cancer
Interventions
- Biological: Nivolumab — also filed as Opdivo, BMS-936558
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFRecurrence-free Survival (RFS)
measured Up to 49 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed